Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01804530
Other study ID # PLX119-01
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date August 2013
Est. completion date January 24, 2018

Study information

Verified date August 2018
Source Plexxikon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.


Description:

Part 1. Open-label, sequential PLX7486 TsOH single-agent dose escalation in approximately 60 patients with solid tumors.


Recruitment information / eligibility

Status Terminated
Enrollment 59
Est. completion date January 24, 2018
Est. primary completion date January 24, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria

- Male or female =18 years old

- Patients with histologically confirmed solid tumors who:

o Part 1: have tumor progression following standard therapy, have treatment-refractory disease, or for whom there is no effective standard of therapy

- Women of child-bearing potential must have a negative pregnancy test within 7 days of initiation of dosing and must agree to use an acceptable method of birth control. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for =1 year. Fertile men must also agree to use an acceptable method of birth control while on study drug and up to 3 months after the last dose of study drug.

- All associated toxicity from previous or concurrent cancer therapy must be resolved (to =Grade 1 or Baseline) prior to study treatment administration

- Patients with stable, treated brain metastases are eligible for this trial. However, patients must not have required steroid treatment for their brain metastases within 30 days of Screening.

- Willing and able to provide written informed consent prior to any study related procedures and to comply with all study requirements

- Karnofsky performance status =70%

- Life expectancy =3 months

- Adequate hematologic, hepatic, and renal function

Exclusion Criteria

- Other than the primary malignancy, active cancer (either concurrent or within the last 3 years) that requires non-surgical therapy (e.g., chemotherapy or radiation therapy), with the exception of surgically treated basal or squamous cell carcinoma of the skin, melanoma in situ, or carcinoma in-situ of the cervix

- Chemotherapy within 28 days prior to C1D1

- Biological therapy within 5 half-lives prior to C1D1

- Radiation therapy within 28 days or 5 half-lives prior to C1D1, whichever is longer

- Investigational drug use within 28 days or 5 half-lives, whichever is longer, prior to C1D1

- Part 1 only: (a) Patients with active or a history of glucose intolerance or diabetes mellitus and (b) Hemoglobin A1c =7%

- =Grade 2 sensory neuropathy at baseline

- Uncontrolled intercurrent illness (i.e., active infection) or concurrent condition that, in the opinion of the Investigator, would interfere with the study endpoints or the patient's ability to participate

- Refractory nausea and vomiting, malabsorption, small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption

- Mean QTcF =450 msec (for males) or =470 msec (for females) at Screening

- The presence of a medical or psychiatric condition that, in the opinion of the Principal Investigator, makes the patient inappropriate for inclusion in this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PLX7486 TsOH
PLX7486 TsOH capsules, 50mg

Locations

Country Name City State
United States John Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland
United States Massachusetts General Hospital Cancer Center Boston Massachusetts
United States Medical University of South Carolina Charleston South Carolina
United States Ronald Reagan UCLA Medical Center Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Plexxikon

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of PLX7486 as single agent as measured by adverse events and serious adverse events. 1 year
Primary Area under the plasma concentration-time curve [AUC0-t, AUC0-inf] Area under the plasma concentration-time curve [AUC0-t, AUC0-inf] will be used to assess the pharmacokinetic profile of PLX7486. 1 year
Primary Peak concentration (Cmax) Peak concentration (Cmax) will be used to assess the pharmacokinetic profile of PLX7486. 1 year
Primary Time to peak concentration (Tmax) Time to peak concentration (Tmax) will be used to assess the pharmacokinetic profile of PLX7486. 1 year
Primary Half life (t1/2) Half life (t1/2) will be used to assess the pharmacokinetic profile of PLX7486. 1 year
Primary Terminal elimination rate constant (Kel) Terminal elimination rate constant (Kel) will be used to assess the pharmacokinetic profile of PLX7486. 1 year
Secondary Duration of response (DOR) Duration of response is defined as the number of days from the date of initial response (PR or better) to the date of first documented disease progression/relapse or death, whichever occurs first. 1 year
Secondary Progression-Free Survival (PFS) Progression-free survival (PFS) is defined as the number of days from start of therapy to the date of documented disease progression/relapse, whichever occurs first. 6 month
Secondary Overall Response Rate (ORR) 1year
Secondary Overall Survival (OS) 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2